PLAINSBORO, NJ, USA I August 15, 2025 I Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...

CHATHAM, NJ, USA I August 15, 2025 I Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential ...

BEIJING, China I August 15, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies ...

BASEL, Switzerland I August 12, 2025 I Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus ...

BOSTON, MA, USA I August 14, 2025 I Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...

NEW YORK, NY, USA I August 14, 2025 I Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, ...

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung ...

CULVER CITY, CA, USA I Augus 13, 2025 I ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I ...

Novel Mechanism Demonstrates Clinically Meaningful Prevention of Weight Rebound and Metabolic Benefits After Stopping GLP-1 Therapy ...

VE707: Vedanta is also advancing VE707 to prevent infections by multidrug-resistant organisms that affect a wide range of vulnerable populations in areas such as oncology, urology, transplantation, ...